TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera's ongoing collaboration with Clearmind Medicine Inc. ("Clearmind"), a patent application has been filed by Clearmind with the Intellectual Property Department  in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative

Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030 Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat

TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disea

TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. ("CliniQ") and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT)

Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. ("SciSparc" or the "Company") (NASDAQ:SPRC), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it intends to effect a one-for-nine (1-for-9) reverse share split (the "Reverse Share Split") of the Company's issued and outstanding ordinary shares, no par value per share (the "Ordinary Shares"), effective at the market open on March 4, 2026. The Ordinary Shares will continue to t

NeuroThera's Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the United States Patent and Trademark Office has granted a U.S. patent for NeuroThera's proprietary combination of antimicrobials and cannabinoids. This patent covers innovative compositions and method

SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the closing of the acquisition of an IP portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo"). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat

SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the signing of a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo"). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fu

TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it has received a written notification (the "Notification Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, listing Rule 5550(b)(1), due to its failure to maintain a minimum of $2,500,000 in stockholders' equity. In the Company's Form 6-K dated No

6-K - SciSparc Ltd. (0001611746) (Filer)

6-K - SciSparc Ltd. (0001611746) (Filer)

6-K - SciSparc Ltd. (0001611746) (Filer)

F-3 - SciSparc Ltd. (0001611746) (Filer)

6-K - SciSparc Ltd. (0001611746) (Filer)

EFFECT - SciSparc Ltd. (0001611746) (Filer)

6-K - SciSparc Ltd. (0001611746) (Filer)

6-K - SciSparc Ltd. (0001611746) (Filer)

F-3 - SciSparc Ltd. (0001611746) (Filer)

6-K - SciSparc Ltd. (0001611746) (Filer)

As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

SC 13G - SciSparc Ltd. (0001611746) (Subject)

SC 13G - SciSparc Ltd. (0001611746) (Filed by)

SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that the Company's board of directors resolved to initiate a process to review potential strategic transactions with the goal of maximizing shareholder value. Potential strategic transactions to be explored and evaluated during the review process may include additional investments in innovative companies, acquisitions, a strategic partnership with one or more parties, or the licensing of one or more of the Company's pr